Business Sweden: “Companies have a lot to offer in data-driven precision medicine”

Data-driven precision medicine can potentially solve major healthcare problems, states Business Sweden in a new report on the subject.

The top five most expensive drugs in 2025

New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...

Allogene discontinues investigational antibody following patient death

U.S. biotechnology company Allogene Therapeutics is fully discontinuing the use of its experimental antibody ALLO-647 following the death of a patient in its pi...

Merck KGaA acquires American company in €3.0 billion deal

Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.

Sensorer som lossnar och buggar i appar – fler klagomål på medicinteknik

Läkemedelsverkets nya e-tjänst för anmälan av problem med medicintekniska produkter har lett till en markant ökning av rapporter från privatpersoner. Särskilt m...

New diagnostic rules raise concerns

In a panel discussion, several voices from academia and the industry expressed concerns about the transition to the new regulatory framework for in-vitro diagno...

AstraZeneca´s Trixeo approved in the UK using propellant with near-zero Global Warming Potential

AstraZeneca has received approval in the United Kingdom for its inhaled respiratory medicine Trixeo Aerosphere with a new propellant that is reported to reduce ...

Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed

Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.

Rise and Scantox cease conducting animal testing in Stockholm

Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs ar...

12 000 jobb borta från Bayer på två år

Över 12 000 tjänster har försvunnit på Bayer sedan en omfattande omstrukturering av kemi- och läkemedelskoncernen inleddes för två år sedan.

Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...

A new giant among our microscopes

Two technologies in one machine.

Dödsstraff yrkas för mordet på amerikansk vård-vd

Åklagarsidan kommer att yrka på dödsstraff för Luigi Mangione, som står inför rätta för mordet på sjukvårdsförsäkringsbolaget United Healths vd Brian Thompson i New York i fjol....

The Future of Swedish & Danish Life Science (2026)

Organize and Manage Digital Classrooms

Create engaging lessons with ZEISS Labscope Teacher.

CT technology for when the inside matters

ZEISS METROTOM 1 now at #HandsOnMetrology.

Cantargia får snabbspår för antikroppen nadunolimab

Lundabaserade biotechbolaget Cantargia har beviljats Fast Track-status i USA för snabbare utveckling och granskning av sin läkemedelskandidat avsedd för behandl...

ZEISS Quality Innovations at CONTROL

May 6-9, 2025 in Stuttgart.

Björn Arvidsson will lead research and innovation in Region Uppsala

The Swedish life science profile Björn Arvidsson has been appointed Director of Research and Innovation for Region Uppsala.

Novo Nordisk planerar att kapa kostnader när konkurrensen hårdnar

Novo Nordisk slopar två fetmaläkemedel som en del av en omfattande översyn av forskningsportföljen. Samtidigt meddelar att avgående vd:n Lars Fruergaard Jørgens...

Positivt USA-besked om Alzecures smärtpreparat

Alzecure har beviljats särläkemedelsstatus i USA för smärtpreparatet ACD440.

High-tech companies are increasingly focusing on health

Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more...

New features in ZEISS CALYPSO 2024

ZEISS CALYPSO is your universal software for dimensional metrology applications.

Stärkt kassa tar Amferia vidare i kampen mot resistenta bakterier

Mölndalsbolaget Amferia har tagit in 1,2 miljoner euro, motsvarande drygt 14 miljoner kronor, för fortsatt utveckling av antibakteriella lösningar som alternati...